GlassScriptPhysician profile
Taylor L Perry
NPI 1356987135
$1,883.84
in general payments reported to CMS, 2019-2025
19 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2023: $469 · 2024: $897 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $352.38 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $183.89 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $157.62 | 2023-2025 | Evenity, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $124.45 | 2021 | |
| Abbott Laboratories | $122.34 | 2024-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $121.83 | 2023-2025 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $120.92 | 2023-2024 | |
| Exact Sciences Corporation | $114.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $108.85 | 2023-2025 | Rexulti |
| Abbvie INC. | $105.28 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.15 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $65.10 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Pfizer INC. | $63.03 | 2024-2025 | |
| Corium, LLC | $41.27 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $34.64 | 2023-2024 | Gardasil 9, Vaxneuvance, Gardasil |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $33.99 | 2025 | Veozah |
| Esperion Therapeutics, INC. | $20.72 | 2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $17.83 | 2023 | Spravato |
| Lundbeck LLC | $14.17 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.